DEFA14A: Xilio Therapeutics Sets Date for 2024 Annual Meeting, Outlines Voting Matters

Xilio Therapeutics has scheduled its 2024 Annual Meeting for June 13, 2024, and is seeking stockholder votes on the election of directors and ratification of its independent accounting firm.

Summary

• Xilio Therapeutics will hold its 2024 Annual Meeting on June 13, 2024.
• Stockholders are being asked to vote on the election of two Class III directors, Paul J. Clancy and Christina Rossi, to serve until the 2027 Annual Meeting.
• The company is also seeking ratification of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2024.
• Stockholders can vote in advance of the meeting until June 12, 2024, either online or by requesting printed materials.
• The proxy materials, including the 2023 Annual Report, Notice of Meeting, and 2024 Proxy Statement, are available online.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, indicating a neutral sentiment. It's a routine communication for corporate governance.

Future Outlook

The document outlines the standard procedures for an annual meeting, focusing on governance matters and shareholder voting.

Industry Context

This is a standard proxy statement related to an annual meeting, a routine event for publicly traded companies to address corporate governance matters.

Stakeholder Impact

• Shareholders are directly impacted through their voting rights on key company decisions.
• The outcome of the votes will influence the composition of the Board of Directors and the selection of the independent accounting firm.

Next Steps

• Stockholders are encouraged to review the proxy materials and vote on the proposals.
• The company will proceed with the Annual Meeting on June 13, 2024.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Accounting Firm, Xilio Therapeutics, Voting